<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/46387D84-F71E-4B7D-8C7D-9C288F113510"><gtr:id>46387D84-F71E-4B7D-8C7D-9C288F113510</gtr:id><gtr:name>Imperial College London</gtr:name><gtr:department>Dept of Medicine</gtr:department><gtr:address><gtr:line1>South Kensington Campus</gtr:line1><gtr:line2>Exhibition Road</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>SW7 2AZ</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/46387D84-F71E-4B7D-8C7D-9C288F113510"><gtr:id>46387D84-F71E-4B7D-8C7D-9C288F113510</gtr:id><gtr:name>Imperial College London</gtr:name><gtr:address><gtr:line1>South Kensington Campus</gtr:line1><gtr:line2>Exhibition Road</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>SW7 2AZ</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/95D38EA8-32C4-4BC9-AB30-FD0E25B6E75B"><gtr:id>95D38EA8-32C4-4BC9-AB30-FD0E25B6E75B</gtr:id><gtr:firstName>Rachel</gtr:firstName><gtr:surname>Troke</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MR%2FJ010936%2F1"><gtr:id>C84E63E9-3780-4A10-A2DD-D50755430A90</gtr:id><gtr:title>The 'Medical Bypass': a new treatment for obesity and diabetes</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Fellowship</gtr:grantCategory><gtr:grantReference>MR/J010936/1</gtr:grantReference><gtr:abstractText>About 1 in 4 people in the UK are obese, and this causes them to develop diabetes and other diseases. The problem is becoming increasingly common, and causes a great deal of illness and premature death. There is currently only one weakly effective drug available for obesity. We desperately need a drug that is effective. We know that gastric bypass surgery works well for the treatment of obesity and diabetes, but is expensive and can have fatal complications. Bypass surgery works by increasing the release of the gut's natural satiety hormones. In order to obtain the benefits of surgery without the procedure and its associated risks, I propose to administer a combination of these satiety hormones to produce a 'medical bypass'. I will test this medical bypass treatment in obese animals to demonstrate that it makes them lose weight and improves their diabetes. This will then provide the vital proof to justify a trial of the medical bypass in overweight patients.</gtr:abstractText><gtr:technicalSummary>Obesity and Type 2 diabetes are massive health problems worldwide. There is no adequate medical treatment for obesity. Bariatric surgery is successful in reducing weight and producing remissions in diabetes by increasing the circulating levels of gut hormones which, acting in concert, suppress appetite, increase energy expenditure and improve carbohydrate metabolism. However, surgery is expensive and has high morbidity and mortality rates.

I will test whether a 'medical bypass' combination of newly developed long-lasting analogues of the gut hormones, peptide YY(PYY), glucagon-like peptide-1 (GLP-1) and oxyntomodulin (OXM), can reproduce the effect of a surgical bypass and thus provide a medical treatment for obesity. I will use a validated animal model of obesity, the diet-induced obese Wistar rat. 

I will initially compare the effects of surgical bypass vs 'medical bypass' on food intake and body weight. Levels of GLP-1, OXM and PYY will be measured after surgical bypass in one group of animals. In another group, I will mimic these levels with an appropriate dose of analogue and then assess the effects of the two treatments on food intake and body weight. 

Three months treatment with the analogue combination will then be assessed for its effects on (a) food intake; (b) body weight; (c) energy expenditure as assessed by a Comprehensive Lab Animal Management system; (d) glucose tolerance; (e) body composition and (f) neuronal activation in the hypothalamus and brainstem, assessed by immunohistochemistry for the neuronal activation marker c-fos.

By understanding the effects of the medical bypass, I will obtain proof-of-concept in animals that will enable this new therapy to be translated into a successful medical treatment for obesity and type 2 diabetes.</gtr:technicalSummary><gtr:potentialImpactText>Obesity, and with it diabetes, is rapidly becoming a major worldwide health problem. The long term complications of obesity are many, and in addition to diabetes include ischaemic heart disease, stroke and cancer. Obesity has been proven to reduce both quality of life, and life expectancy. Surgical gastric bypass can improve or in some cases reverse the comorbidities associated with obesity, and has therefore become a valuable treatment strategy. However, surgical bypass is costly and does not come without risk, carrying a significant morbidity and 1/300 mortality. It is also irreversible. Our research aims to devise a safe and effective alternative in the 'medical bypass'

The direct beneficiaries of this research will be obese members of the population, a group which currently represents 25% of the UK population. This number continues to grow and is predicted to reach 50-60% by 2050. By demonstrating that these combinations of long acting hormones are able to give sustained weight loss and remission of diabetes in diet-induced obese rats, I will provide proof of concept to justify a trial of the medical bypass treatment in humans. 

The ultimate goal of this research is to devise an effective treatment for obesity and diabetes that will prove to be safe and cost effective.</gtr:potentialImpactText><gtr:fund><gtr:end>2016-04-08</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2012-06-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>253923</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Press Release resulting from Oral Presentation at Scientific Meeting</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>6D575A8E-B767-4D83-8818-388A0482B769</gtr:id><gtr:impact>Oral presentation of research results at a scientific meeting (BES, Harrogate 2013). 
Title: Co-infusion of low-dose glucagon-like peptide-1 (GLP-1) and glucagon in man results in a reduction in food intake 
Authors:Jaimini Cegla*, Rachel C. Troke*, Ben Jones, George Tharakan, Julia Kenkre, Katherine A. McCullough, Chung Thong Lim, Nassim Parvizi, Mohamed Hussein, Edward S. Chambers, James Minnion, Joyceline Cuenco, Mohammad A. Ghatei, Karim Meeran, Tricia M. Tan, Stephen R. Bloom

Results noted by BES press officer, and press release issued. Coverage in national newspaper and internationally via the internet</gtr:impact><gtr:outcomeId>HMFBHUnL6Zf</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Paper Presentation</gtr:presentationType><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:url>http://www.endocrinology.org/meetings/2013/sfebes2013/abstracts.aspx  http://www3.imperial.ac.uk/newsandeventspggrp/imperialcollege/newssummary/news_18-3-2013-17-37-33  http://www.blisstree.com/2013/03/19/food/diet-drug-no-side-effects  http://www.banglad</gtr:url><gtr:year>2013</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>537F1BBC-695F-45EF-B110-D67326349B81</gtr:id><gtr:title>Coinfusion of low-dose GLP-1 and glucagon in man results in a reduction in food intake.</gtr:title><gtr:parentPublicationTitle>Diabetes</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fc62af1c970f710b6f0b1e5c0bbd1599"><gtr:id>fc62af1c970f710b6f0b1e5c0bbd1599</gtr:id><gtr:otherNames>Cegla J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0012-1797</gtr:issn><gtr:outcomeId>5450f4816e0872.60472395</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F56138B8-78C5-4C77-BDAE-F618B50E80C3</gtr:id><gtr:title>Combination of peptide YY3-36 with GLP-1(7-36) amide causes an increase in first-phase insulin secretion after IV glucose.</gtr:title><gtr:parentPublicationTitle>The Journal of clinical endocrinology and metabolism</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b506e62dbe7269359b599b222c300632"><gtr:id>b506e62dbe7269359b599b222c300632</gtr:id><gtr:otherNames>Tan TM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0021-972X</gtr:issn><gtr:outcomeId>5450f565bc3349.58723201</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B64FC45B-7D63-45E4-B8E5-4370520BB9F0</gtr:id><gtr:title>The future role of gut hormones in the treatment of obesity.</gtr:title><gtr:parentPublicationTitle>Therapeutic advances in chronic disease</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/91f53b35c1bc6a6ce45f3028063a720d"><gtr:id>91f53b35c1bc6a6ce45f3028063a720d</gtr:id><gtr:otherNames>Troke RC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>2040-6223</gtr:issn><gtr:outcomeId>KdJABx3UNzM</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MR/J010936/1</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>7C58A707-1BF6-4573-A44F-30B271C80813</gtr:id><gtr:percentage>20</gtr:percentage><gtr:text>Cancer</gtr:text></gtr:healthCategory><gtr:healthCategory><gtr:id>D4FDB752-4E9C-491F-9C63-B7D7F6F95417</gtr:id><gtr:percentage>20</gtr:percentage><gtr:text>Cardiovascular</gtr:text></gtr:healthCategory><gtr:healthCategory><gtr:id>160D22D0-5677-4513-A0AC-7F3526B7F336</gtr:id><gtr:percentage>20</gtr:percentage><gtr:text>Metabolic and Endocrine</gtr:text></gtr:healthCategory><gtr:healthCategory><gtr:id>D81A471F-556F-4570-BF6A-5D197943223C</gtr:id><gtr:percentage>20</gtr:percentage><gtr:text>Oral and Gastrointestinal</gtr:text></gtr:healthCategory><gtr:healthCategory><gtr:id>A77DAE3A-499B-4F46-971D-6C82F51F9C2E</gtr:id><gtr:percentage>20</gtr:percentage><gtr:text>Stroke</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>8F896112-5A04-4A11-A9F0-2B446D9AAC8A</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>5.1  Pharmaceuticals</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>